Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KARS1 | Q15046 | 3/20 | 0.66 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.59 |
| ▸ | USP2 | O75604 | 3/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | TP53 | P04637 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.56 |
| ▸ | FDPS | P14324 | 6/20 | 0.50 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.50 |
| ▸ | BCL9 | O00512 | 3/20 | 0.49 |
| ▸ | CTNNB1 | P35222 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | PTGES | O14684 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sempervirol SCHEMBL10524412 | 1.00 | KARS1 (0.66) | KARS1CYP19A1USP2CYP3A4MAPT | |
| Sempervirol SCHEMBL10524413 | 1.00 | KARS1 (0.66) | KARS1CYP19A1USP2CYP3A4MAPT | |
| Ferruginol SCHEMBL5315022 | 0.95 | KARS1 (0.73) | KARS1CYP19A1USP2CYP3A4MAPT | |
| Ferruginol SCHEMBL13423521 | 0.95 | KARS1 (0.73) | KARS1CYP19A1USP2CYP3A4MAPT | |
| Ferruginol SCHEMBL155580 | 0.95 | KARS1 (0.73) | KARS1CYP19A1USP2CYP3A4MAPT | |
| SCHEMBL18290298 | 0.83 | KARS1 (0.58) | KARS1CYP19A1USP2CYP3A4MAPT | |
| SCHEMBL17861419 | 0.82 | POLA1 (0.49) | KARS1CYP19A1USP2CYP3A4MAPT | |
| 18-Hydroxyferruginol SCHEMBL18290210 | 0.81 | KARS1 (0.67) | KARS1USP2CYP3A4MAPTMEN1 | |
| 18-Hydroxyferruginol SCHEMBL32666150 | 0.81 | KARS1 (0.67) | KARS1USP2CYP3A4MAPTMEN1 | |
| SCHEMBL21444399 | 0.80 | KARS1 (0.57) | KARS1CYP19A1USP2CYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12503448-B2 | Antibacterial and antiparasitic quinoxaline-2,3-diamine derivatives | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2025-12-23 | — | — | US | disclosed |
| EP-4580627-A1 | TREATMENT OF FASCIOLOSIS | Intervet International B.V. (NL) | 2025-07-09 | — | — | EP | disclosed |
| CN-114514229-B | Antibacterial and antiparasitic quinoxaline-2, 3-diamine derivatives | 阿伯里斯特维斯大学 | 2024-11-22 | — | — | CN | disclosed |
| CN-118684667-A | Compounds for the treatment of fasciolopsis | 默克专利股份有限公司 | 2024-09-24 | — | — | CN | disclosed |
| CN-118575080-A | Novel potency assays for antibody-based drugs and methods useful therefor | 神经免疫有限公司 | 2024-08-30 | — | — | CN | disclosed |
| US-12060355-B2 | Compounds for use in the treatment of fascioliasis | MERCK PATENT GMBH (DE) | 2024-08-13 | — | — | US | disclosed |
| CN-112512636-B | Compounds for the treatment of fasciolopsis | 默克专利股份有限公司 | 2024-06-18 | — | — | CN | disclosed |
| WO-2024047241-A1 | TREATMENT OF FASCIOLOSIS | INTERVET INTERNATIONAL B.V. (NL) | 2024-03-07 | — | — | WO | disclosed |
| US-20220259159-A1 | ANTIBACTERIAL AND ANTIPARASITIC QUINOXALINE-2,3-DIAMINE DERIVATIVES | ABERYSTWYTH UNIVERSITY (GB) | 2022-08-18 | — | — | US | disclosed |
| EP-3972586-A1 | ANTIBACTERIAL AND ANTIPARASITIC QUINOXALINE-2,3-DIAMINE DERIVATIVES | Aberystwyth University (GB) | 2022-03-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220259159-A1 | ANTIBACTERIAL AND ANTIPARASITIC QUINOXALINE-2,3-DIAMINE DERIVATIVES | FPR3, RPS12, FPR2 | KARS1 1199/4885CYP19A1 3346/4885USP2 3192/4885 |
| US-12060355-B2 | Compounds for use in the treatment of fascioliasis | SLC10A1, SLC10A2, MGST3 | KARS1 3533/4885CYP19A1 3621/4885USP2 3358/4885 |
| US-12503448-B2 | Antibacterial and antiparasitic quinoxaline-2,3-diamine derivatives | FPR3, RPS12, FPR2 | KARS1 1199/4885CYP19A1 3346/4885USP2 3192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.